Expression of the tumor antigens NY-ESO-1, tyrosinase, MAGE-A3, and TPTE in pediatric and adult melanoma: a retrospective case control study

• DOI: 10.1007/s00428-024-03846-0
• Publication Date: 2024-06-18T20:09:48Z
• Authors: Stephan Forchhammer; Oltin Tiberiu Pop; Matthias Hahn; Valentin Aebischer; Christian M. Seitz; Christopher Schro...; Alexandra Liebmann; Michael Abele; Hannah Wild; Ewa Bien; Michal Kunc; Dominik T. Schneider; Katarina Cuk; Isabel Büttel; Carina Flemmig; Magdalena Peters; Mark Laible; Patrick Brück; Özlem Türeci; Ugur Sahin; Lukas Flatz; Ines B. Brecht
• Keywords: Male; Adult; 0301 basic medicine; Skin Neoplasms; Adolescent; 610; Young Adult; 03 medical and health sciences; Antigens, Neoplasm; 616; Biomarkers, Tumor; Humans; Child; Melanoma; Retrospective Studies; Aged; Monophenol Monooxygenase; Membrane Proteins; Infant; Middle Aged; Neoplasm Proteins; Case-Control Studies; Child, Preschool; Original Article; Female

Abstract Tumor-associated antigens (TAAs) are potential targets for T cell-based immunotherapy approaches in cutaneous melanoma. BNT111, an investigational lipoplex-formulated mRNA-based therapeutic cancer vaccine encoding melanoma TAAs NY-ESO-1, tyrosinase, MAGE-A3, and TPTE, is undergoing clinical testing adults. Expression of these pediatric unclear but a prerequisite feasibility this treatment approach children with Our main objective was to characterize expression those melanomas compared control cohorts. In retrospective case study, protein transcript TPTE were analyzed cohort 25 melanomas, 31 young adults, 29 adult 30 benign melanocytic nevi using immunohistochemical staining digital pathology (QuPath) reverse transcription quantitative PCR. Based on IHC analysis, expressed tyrosinase (100.0%), (44.0%), MAGE-A3 (12.0%), NY-ESO-1 (8.0%). Young (96.8%), (19.4%), (3.2%). Adult (86.2%), (75.9%), (48.3%), (48.3%). Childhood only (93.3%). prevalence individual did not differ between subtypes melanoma, no association prognosis found. All four albeit lesser extent than These data support the possibility investigating vaccines targeting